Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on December 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on November 13th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Cigna Group (NYSE:CI) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Xcel Energy (NASDAQ:XEL) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 11/13/2025.

Eli Lilly and Company Trading Up 0.7%

Shares of LLY stock traded up $6.96 during trading hours on Friday, reaching $1,063.84. 1,366,252 shares of the stock traded hands, compared to its average volume of 4,019,222. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $1.01 trillion, a PE ratio of 52.08, a PEG ratio of 1.31 and a beta of 0.37. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The business has a fifty day moving average price of $956.00 and a 200 day moving average price of $828.10.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Institutional Trading of Eli Lilly and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company during the first quarter worth about $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new position in Eli Lilly and Company during the second quarter valued at approximately $27,000. Vermillion & White Wealth Management Group LLC increased its stake in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares in the last quarter. Evolution Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the second quarter worth $29,000. Finally, Steph & Co. boosted its position in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Key Stores Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Orforglipron Phase‑3 “ATTAIN‑MAINTAIN” met primary and all key secondary endpoints — patients switching from injectable GLP‑1s (Wegovy/Zepbound) largely kept their weight loss; Lilly has submitted orforglipron to the FDA for obesity, which materially expands addressable market if approved. Read More.
• Positive Sentiment: Major media and trade outlets amplify the orforglipron result and FDA filing — coverage highlights that an effective daily oral GLP‑1 could change prescribing patterns and patient uptake versus injectables, supporting revenue upside and market share gains. Read More.
• Positive Sentiment: Bank and boutique analyst actions: BofA upgraded/Lilly seen as having “room for stock upside” with multibillion sales potential for oral obesity drugs; Daiwa issued an upgrade — these lend credibility to higher earnings forecasts and help near‑term sentiment. Read More. | Read More.
• Neutral Sentiment: Pipeline breadth: Lilly advanced eloralintide into Phase‑3 and reported progress on other candidates (e.g., imlunestrant), reinforcing longer‑term growth diversification beyond GLP‑1s. Read More.
• Neutral Sentiment: Marketing and brand moves (Team USA/Olympics content) raise brand visibility but are unlikely to move near‑term fundamentals. Read More.
• Negative Sentiment: Price cuts in Canada: Lilly is cutting prices of Mounjaro and Zepbound by ~20%+ in Canada per reports — a potential hit to regional revenue and a sign of pricing pressure/payer negotiations that investors should watch for other markets. Read More.
• Negative Sentiment: Notable selling: A high‑profile investor reportedly reduced LLY holdings, which can amplify volatility even if it doesn’t reflect company fundamentals. Read More.

Analyst Ratings Changes

Several research firms have commented on LLY. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Weiss Ratings reissued a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Four analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,141.73.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.